Conversely, miR-320 knockdown decreased lipogenic gene FAS by enhancing LEPR in the cytoplasm and downregulating CD36 transcription in the nucleus, which provided a potential therapeutic target for treating NAFLD in the future. This evidence concerns the gene CD36 and metabolic dysfunction-associated steatotic liver disease.